Follitropin Alfa

Follitropin alfa is a recombinant form of follicle-stimulating hormone, one of the gonadotropins, the hormones released by the pituitary gland that govern the reproductive glands ^[1]. FSH itself is a glycoprotein, a protein decorated with sugar chains, and follitropin alfa reproduces the human hormone by growing it in cultured mammalian cells that have been genetically engineered to make it ^[1][2]. This recombinant approach yields a consistent, highly purified product, in contrast to earlier gonadotropin preparations that were extracted from the urine of donors ^[2]. Because it is a protein, it would be broken down if swallowed and so is administered by injection under the skin ^[1].

Recombinant FSH was developed to provide a purer and more standardised alternative to urine-derived hormones ^[2]. Follitropin alfa was first approved in Europe in the mid-1990s and is sold chiefly under the brand name Gonal-f ^[1]. A number of biosimilar versions have since been introduced, such as Ovaleap and Bemfola, and it is also combined with recombinant luteinising hormone in a product used for certain patients ^[1]. It is closely related to follitropin beta, another recombinant FSH made in a similar way ^[1].

The hormone is used mainly in the treatment of infertility ^[1][2]. In women it is given to stimulate the ovaries, either to induce ovulation in those who do not ovulate on their own or, more often, to grow multiple follicles during the controlled ovarian stimulation phase of assisted reproduction such as in vitro fertilisation and intracytoplasmic sperm injection ^[1][2]. In men with hypogonadotropic hypogonadism, it can be used alongside another hormone to support sperm production ^[1]. A large Cochrane systematic review comparing recombinant FSH with the older urinary gonadotropins found no meaningful difference between them in live birth rates or in the rate of ovarian hyperstimulation, concluding that the choice between products can reasonably rest on availability, convenience, and cost ^[2]. Later trials of biosimilar FSH products have used follitropin alfa as the established comparator ^[3].

The most important risk of FSH treatment is ovarian hyperstimulation syndrome, in which the stimulated ovaries become swollen and leak fluid into the abdomen; this ranges from mild bloating and discomfort to, rarely, a serious condition requiring hospital care ^[1][2]. Stimulating the growth of several follicles also raises the chance of a multiple pregnancy ^[1]. More ordinary effects include reactions at the injection site and a sense of fullness or tenderness in the lower abdomen ^[1]. Treatment is therefore monitored closely with ultrasound scans and hormone measurements so that the ovarian response can be tracked ^[2].

Follitropin alfa is prescription only and used under fertility specialist care. Its key risk is ovarian hyperstimulation syndrome, an overresponse in which the ovaries enlarge and fluid shifts into the abdomen and chest; severe cases bring pain, bloating, clots, and breathing difficulty and need urgent treatment. It also raises the chance of multiple pregnancy. Other effects include injection site reactions, headache, mood changes, breast tenderness, ovarian cysts, and pelvic discomfort. Careful monitoring with ultrasound and blood estradiol lets the team tune the dose to reduce these risks. It is avoided when there is uncontrolled thyroid or adrenal disease, an unexplained ovarian enlargement or cyst, undiagnosed vaginal bleeding, or a hormone-sensitive tumor. Treatment is paused or stopped if the ovaries respond too strongly.

Follitropin alfa was developed by the Swiss-Italian company Serono as a recombinant version of human follicle-stimulating hormone, produced in genetically engineered Chinese hamster ovary cells carrying the human FSH genes. Launched under the brand name Gonal-f in the mid-1990s, it represented a major advance over the earlier gonadotropin preparations, which had to be laboriously purified from the urine of postmenopausal women.

Because the recombinant hormone could be manufactured to a consistent purity and delivered free of luteinising hormone activity, clinicians gained the ability to dose follicle-stimulating activity precisely and adjust it from cycle to cycle, a capability central to modern in vitro fertilisation. It quickly became a mainstay of assisted reproduction and is also used to stimulate sperm production in certain forms of male infertility. Its patents having expired, follitropin alfa is now also available as biosimilar products such as Bemfola and Ovaleap.

Follitropin alfa is highly regarded in reproductive medicine for the consistency, purity, and precise dosing it brought to ovarian stimulation, qualities that the older urine-derived products could not reliably match. Studies have found it to be at least as effective as those earlier preparations, and its availability in ready-to-use injection pens has made self-administration considerably more manageable for patients undergoing fertility treatment.

The arrival of biosimilar versions has broadened access and introduced price competition. Honest appraisal notes that treatment is not without burden: it requires repeated subcutaneous injections, close monitoring by ultrasound and blood tests, and vigilance for ovarian hyperstimulation syndrome and multiple pregnancy, and the cost of a cycle remains substantial. Within the demanding context of assisted reproduction, however, it is viewed as a dependable and well validated tool.